Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the upcoming lead plaintiff deadline on April 7, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 7, 2026 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4]. Group 3: Case Background - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like human papillomavirus (HPV) [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application (BLA) to the FDA, which were overstated [5].

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=183596&from=3 CLA ...

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--Law Offices of Frank R. Cruz Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action. ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Inovio Pharmaceuticals, Inc. ("Inovio†or the "Company†) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the "Class Period†). Inovio investors have until April 7, 2026 to file a lead plaintiff motion. IF YOU SUFFERED. ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and certain officers.   The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 26-cv-00803, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Inovio securities between October 10, 2023 ...

New York, New York--(Newsfile Corp. - February 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 7, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may lack the necessary experience [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Specifics - Inovio Pharmaceuticals is described as a biotechnology company focused on DNA medicines for diseases like HPV [5]. - The lawsuit alleges that Inovio made false or misleading statements regarding the manufacturing of its CELLECTRA device and the prospects of its INO-3107 Biologics License Application, which were overstated [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is a deadline of April 7, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [4]. - It is claimed that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4]. - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [5][6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, due to alleged misleading statements regarding the company's manufacturing and regulatory prospects [1][5]. Company Overview - Inovio Pharmaceuticals is described as a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating diseases, including those associated with human papillomavirus (HPV) [5]. Legal Allegations - The lawsuit claims that during the Class Period, Inovio made false and misleading statements, including: 1. Deficiencies in the manufacturing of Inovio's CELLECTRA device [5]. 2. Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. 3. Insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [5]. 4. Overstated regulatory and commercial prospects for INO-3107 [5]. - The lawsuit asserts that these misstatements led to investor damages when the true information became public [5]. Class Action Participation - Investors who purchased Inovio securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly [3][6].